HEPATIC DAMAGE DURING CHLORPROPAMIDE THERAPY

Publisher Website
Google Scholar
Abstract
Recently a new arylsulfonylurea, chlorpropamide (Diabinese), has been released for the management of diabetes mellitus. Its mode of action is similar to that of other sulfonylureas, but it has a more potent hypoglycemic effect than tolbutamide and is excreted more slowly. As a result, lower dosages may be used and a fairly constant blood level obtained. Studies of acute and chronic conditions in animals have shown that this drug possesses a low order of toxicity.1 Clinical trial in approximately 2,000 cases, for periods up to one year, indicates that in some patients hepatic function tests may show transient deviations from the normal. In general these abnormalities have not been indicative of serious hepatic dysfunction and have reverted to normal even when the drug therapy was not discontinued. In eight cases jaundice appeared, sometimes associated with a skin rash and eosinophilia. These cases have all occurred within two to five weeks

This publication has 0 references indexed in Scilit: